Incidence of Acute Renal Failure in Patients Using Levetiracetam Versus Other Antiseizure Medications: A Voluntary Post-Authorization Safety Study.

Raphaelle Beau-LejdstromLai San HongXabier Garcia de AlbenizFlorin FloricelJohan LorenzenFrancois BonfittoLinda KalilaniChristian LoeschGraham LuscombeSusanna Perez-GutthannIsabelle MottetNadia Foskett

Published in: Drug safety (2022)

The rate of ARFs in ASM new users was very low. In patients without prior ASMs, the estimated difference in risk of ARF associated with initiation of levetiracetam versus initiation of other ASMs was small, with 95% CIs compatible with small protective or harmful effects. In patients receiving polytherapy, the difference was compatible with the null and the 95% CI with small protective or harmful effects.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
risk factors
liver failure
patient reported outcomes
intensive care unit
hepatitis b virus